|Day Low/High||105.95 / 107.25|
|52 Wk Low/High||64.80 / 125.86|
KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.
- In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1)
Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.
I think M&A activity will pick up markedly going forward across the industry.
Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.
Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.
The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.
The drug company generates about 60% of revenue outside the U.S.
The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.
- Agreements Provide Non-Exclusive License to Samsung Bioepis for HUMIRA-Related Intellectual Property in the U.S. Effective June 30, 2023, and in Other Markets on Different Dates
These names are displaying signs of either bullish or bearish reversal patterns over the past week.
The legal cannabis industry could be worth $24 billion by 2025. Are you willing to pass that up?
Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.
Jim Cramer calls it a tsunami of selling. Not one sector of the stock market got a break in Thursday's tariff-inspired decline.
Here's what you need to know now for Thursday, March 22.
No sector offered respite from Thursday's tariff-inspired selloff.
The biopharma company's shares took a dive on Thursday, March 22, after it said it will not seek accelerated approval for Rova-T in third-line relapsed/refractory small-cell lung cancer.
- Study is among the largest and most comprehensive in multiple myeloma (MM), and will assess outcomes from 1,500 patients with MM and the t(11;14) translocation at participating International Myeloma Foundation sites globally
- Second of two pivotal Phase 3 studies (ELARIS UF-II) met primary efficacy endpoint and all ranked secondary endpoints
Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.
- Endometriosis affects an estimated one in 10 women of reproductive age, but diagnosis can take up to six to 10 years(1,2)
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.